Elekta

Regulatory Filings • Jul 24, 2009

ELEKTA RECEIVES FDA 510 (k) CLEARANCE FOR MONACO VMAT TREATMENT PLANNING SOLUTION

Press Release Stockholm, Sweden, 24 July, 2009

Elekta has received FDA 510(k) clearance for the VMAT (Volumetric Modulated Arc Therapy) enhancement to Monaco®, treatment planning solution.

Monaco treatment planning system, introduces a set of tools to make the treatment planning process easier, more straightforward and clinically reliable. For the clinicians this gives the flexibility and control needed for complex treatment. For the clinic administrator it provides reduced planning time and increased clinical throughput.

"We are extremely proud and very pleased to receive clearance to add this VMAT technique to Monaco in the U.S. market," said Rob Cessac, Product Manager for Elekta CMS Software. "Our continued support and development of leading approaches to cancer treatment promises to create a positive future for clinicians and patients."

The biologically-based Monaco IMRT (Intensity Modulated Radiotherapy) treatment planning system features constrained optimization and dose calculation algorithms and help reduce the time needed to optimize IMRT plans.

Monaco has been available for use clinically for the past two years for step-andshoot IMRT planning. The product was developed in cooperation with Eberhard Karls University Tuebingen in Germany.

For the latest Monaco with VMAT news, visit www.elekta.com.

******

For further information, please contact:

Stina Thorman, Investor Relations, Elekta AB Tel: +46 8 587 257 34, e-mail: stina.thorman@elekta.com

Michelle Lee, Director, Marketing Services, Elekta Inc. Tel: +1 770-670-2447, e-mail: michelle.lee@elekta.com

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated state of the art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.